<?xml version="1.0" encoding="UTF-8"?>
<p id="par0070">
 <italic>In silico</italic> evaluation and preliminary 
 <italic>in vitro</italic> analytical specificity study showed that the Simplexaâ„¢COVID-19 Direct only detects all COVID-19 virus strains, without cross reactivity with other viruses (Simplexa COVID-19 direct, instruction manual available at 
 <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/136286/download" id="intr0005" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/media/136286/download</ext-link>. We established the clinical specificity using clinical samples from patients known to be positive for other respiratory viruses, including Human Coronaviruses (
 <xref rid="tbl0010" ref-type="table">Table 2</xref> ). Results obtained for 20 nasopharyngeal swabs confirmed a 100 % of clinical specificity of the assay, based on the absence of non-specific signal detection due to any type of cross-reactivity event.
</p>
